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B lymphocytes can be activated by many different stimuli. How-
ever, the mechanisms responsible for the signaling and functional
specificities of individual stimuli remain to be elucidated. Here, we
have compared the contribution of the type 1 (p50-dependent) and
type 2 (p52-dependent) NF-B activation pathways to cell survival,
proliferation, homotypic aggregation, and specific gene regulation
of murine primary B lymphocytes. Whereas lipopolysaccharide
(LPS) and B cell activation factor (BAFF) mainly activate the type 1
or type 2 pathways, respectively, CD40 ligand (CD40L) strongly
activates both. Rescue of spontaneous apoptosis is diminished in
p52/ B cells after BAFF stimulation and in p50/c-Rel/ B cells
after LPS stimulation. Interestingly, significant CD40-induced B cell
survival is still observed even in p50/c-Rel/p65/ B cells,
which is correlated with the ability of CD40L to up-regulate Bcl-xL
expression in these cells. CD40L- and LPS-induced B cell prolifera-
tion, as well as up-regulation of proliferation-related genes, how-
ever, are greatly reduced in c-Rel/ and p50/c-Rel/ B cells but
are normal in p52/ B cells. We have further demonstrated that
both c-Rel and p52 are required for CD40-mediated B cell homo-
typic aggregation, which explains well why neither LPS nor BAFF
has this function. Overall, our studies suggest that both type 1 and
type 2 NF-B pathways contribute to the gene expression and
biological program unique for CD40 in B cell activation.
B lymphocytes must integrate multiple biochemical signalingpathways to propagate humoral immune responses.
Throughout this process, B cells are activated by a number of
stimuli with overlapping and unique biochemical pathway acti-
vation potential. The unique contribution of individual receptors
participating in B cell-mediated immune responses continues to
be of great interest. CD40, a member of the tumor necrosis factor
receptor family, plays a central role in humoral immunity (1).
CD40 activation of B cells results in the activation of numerous
biochemical pathways, contributing to biological outcomes in-
cluding enhanced cell survival and proliferation, germinal center
formation, memory B cell development, and Ig isotype switching
and affinity maturation (2). Although we know the contribution
of multiple biochemical signaling pathways to each of these
processes, the mechanisms of CD40’s unique contributions are
still not clear.
CD40 ligation, in common with a number of B cell stimuli,
activates the RelNF-B transcription factors, which are major
regulators of immune and inflammatory responses (3, 4). Five
members of this family exist in mammals: NF-B1 (encoding
p105, which is constitutively processed to p50), NF-B2 (encod-
ing p100, which is processed to p52), RelA (p65), c-Rel, and
RelB. In unstimulated cells, inactive NF-B dimers reside in the
cytoplasm through interaction with one of a family of inhibitory
molecules, collectively termed inhibitors of B (IBs). Appear-
ance in the nucleus of NF-B capable of DNA binding and
transcription enhancement results from the activation of kinases
that phosphorylate key serine residues on IBs, signaling their
ubiquitination and degradation (5). Recent work has shown two
distinct pathways regulating phosphorylation of IB proteins,
resulting in the release of specific and distinct Rel dimers. Type
1 involves activation of the IKK complex, which consists of two
catalytic subunits (IKK and IKK) and one regulatory subunit
(IKKNEMO). Activation of the IKK complex results in the
degradation of IB and -, which release p50:RelA and
p50:cRel dimers (6–9). Type 2 involves activation of NF-B-
inducing kinase, which associates with two IKK molecules.
Together, they recognize and bind to the C-terminal portion of
p100 (also referred to as IB), resulting in p100 processing to
p52 and preferential release of p52:RelB dimers (10, 11). In
recent years, the generation of gene knockout mice has helped
to elucidate the contribution of Rel family members to a diverse
set of cellular responses. Although these studies have revealed
overlapping contributions of Rel proteins to processes such as
proliferation and cell survival, they have also identified distinct
biological roles of individual family members (12–16). As such,
differential activation of the type 1 and type 2 NF-B pathways
has potentially important implications for receptor-mediated
gene induction.
Previous work examined gene expression profiles in B cells
activated by soluble CD40 ligand (sCD40L) and lipopolysaccha-
ride (LPS) (17). We found that the two stimuli activated similar
sets of biochemical pathways but that each also activated a
unique gene set. Recent studies defining the contribution of p52
and RelB have shed light on the tremendous contribution of the
type 2 NF-B pathway to humoral immunity (15, 18). This
finding led to our speculation that the unique gene set induced
by sCD40L, which included genes involved in adhesion, migra-
tion, lymphoid organization, and germinal center formation,
could result from CD40L activation of the type 2 NF-B
pathway, a property that LPS lacks.
In the present study, we analyzed the contribution of type 1
and type 2 NF-B activity to CD40-mediated responses in
primary B cells. Through use of mice deficient in one or more
Rel family member, we show that the type 1 and type 2 NF-B
pathways differentially contribute to CD40-mediated B cell
survival, proliferation, adhesion, and gene expression. We show
that cellular responses common to CD40L and LPS treatment of
B cells require their shared capacity to activate the type 1 NF-B
pathway. In addition, we show that other B cell responses, unique
to CD40, result from the receptor’s ability to activate both arms
of the NF-B pathway.
Materials and Methods
Primary B Cell Isolation and Culture. Spleens were isolated from 8-
to 10-week-old p50/, p50/c-Rel/, p50/c-Rel/p65/,
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and C57BL6J WT control mice or from 129SvPasIcoCrlBR
WT mice, which served as controls for spleens isolated from
c-Rel/ and p52/ mice. To obtain highly pure naı¨ve B cells,
total splenocytes were stained with a biotin-conjugated anti-
CD43 Ab (Pharmingen) followed by streptavidin-conjugated
magnetic microbeads (Miltenyi Biotec, Auburn, CA) and passed
through a depletion-type magnetic sorting column (Miltenyi
Biotec). Unbound cells were collected as the purified resting B
cell sample: 96% pure B220 B cells expressing low levels of
activation markers such as intercellular adhesion molecule 1,
CD23, and B7.2 by fluorescence-activated cell sorter analysis
(data not shown). B cells were cultured in RPMI medium 1640
supplemented with 10% FBS, 50 M 2-mercaptoethanol, and
1% penicillinstreptomycin (Life Technologies, Rockville, MD)
at 37°C under 10% CO2. Cells were stimulated (unless indicated
otherwise) with 15 gml anti-CD40 mAb, FgK-45, 5 gml
LPS, or 100 ngml human B cell activation factor (hBAFF)
(Amgen Biologicals).
Measurement of Cellular Proliferation and Apoptosis. For prolifer-
ation assays, B cells were stimulated at 1.0  106 cells per ml in
96-well plates for 48 h, pulsed with 0.5 Ci (1 Ci  37 GBq) of
[3H]thymidine per well beginning 20 h poststimulation, and
collected on a 96-well filtermat with an automated harvester.
Activity was measured in a 96-well format on a scintillation
counter. For viability assays, B cells were stimulated as above and
cell death was measured through fluorescence-activated cell
sorter analysis after 48 h of culture by double staining with
propidium iodide and FITC-conjugated anti-annexin V Ab. The
percentage of cells in the double-negative quadrant was re-
corded as the viable fraction.
RNA Quantitation. RNA was isolated for Northern blot and quan-
titative real-time PCR (Q-PCR) by using TRIzol (Invitrogen) or
standard guanidinium isothiocyanate methods, respectively. North-
ern blotting was done as described in ref. 19. cDNA fragments
purchased from Research Genetics (Huntsville, AL) were used as
probes for the detection of c-Myc [IMAGE clone (IC) 3663016],
CDK4 (IC 477933), cyclin D2 (IC 2064983), AID (IC 3333637), and
LEF-1 (IC 1446606). Probes cloned via PCR used the following
oligonucleotides amplified from a B cell cDNA library with the
indicated primers: Entactin, 5-TGGAACGAGAGGACATC-
CTTG (forward) and 5-TGCCTCTGGGATTCACCAA (re-
verse); Bcl-xL, 5-ATGTCTCAGAGCAACCGGGA (forward)
and 5-TCACTTCCGACTGAAGAGTG (reverse); and UNG,
5-GGGAAGCCGTACTTCGTCAA (forward) and 5-GAT-
GGGCTTCTTGCCAGACTT (reverse). For Q-PCR analysis, 1
g of RNA was reverse-transcribed by using SuperScript II (In-
vitrogen) according to the manufacturer’s instructions with oli-
go(dT) and random hexamers serving as primers. Q-PCR analysis
was done with the iCycler Thermocycler and Optical System
(Bio-Rad) as described in ref. 20. The primers listed here were used
to amplify a specific 85- to 100-bp fragment of the following genes:
c-Myc, 5CTGCGACGAGAAGAGAGAATTTC (forward) and
5-ACGCTGAATTTCTTCCAGATATCC (reverse); cyclin D2,
5-CCGCCAGGAGCAAATCGAA (forward) and 5-GACTTG-
GATCCGGCGTTATG (reverse).
Immunoblotting. Whole-cell lysate and cell fractionation and
nuclear Western blotting were done as described in ref. 19. B
cells were lysed in radioimmunoprecipitation assay buffer or
fractionation buffer, and protein was quantified by using the
BCA Protein Quantification Kit (Pierce). Thirty micrograms of
protein was added to each lane and separated by either 9% or
12% SDSPAGE. Abs specific for murine Bcl-xL, p65, p52, and
upstream stimulatory factor 2 were obtained from Santa Cruz
Biotechnology. Anti-actin Ab and nonspecific rabbit IgG were
purchased from Sigma. Gels were transferred to nitrocellulose
membranes and immunoblotted according to the Ab manufac-
turer’s recommended instructions.
Flow Cytometry of Intracellular Proteins. For intracellular staining
of Bcl-xL, B cells were fixed and permeabilized by using the
CytoFixPerm Kit (Pharmingen). In short, 5E5 cells were fixed
and permeabilized in 0.25 ml of kit buffer overnight at 4°C. Cells
were washed twice and stained with 10 gml anti-Bcl-xL (Santa
Cruz Biotechnology) or rabbit IgG (Sigma) and 1% normal
mouse serum for 1 h on ice. After washing, cells were then
stained with 5 gml phycoerythrin anti-rabbit IgG for 1 h. Cells
were fixed in 1% paraformaldehyde and analyzed by flow
cytometry by using a FACScan with CELLQUEST software (Bec-
ton Dickinson).
Results
LPS and BAFF Preferentially Activate Type 1 or Type 2 NF-B Pathways,
Respectively, Whereas CD40L Strongly Activates both in Primary B
Cells. CD40, like BAFF and LPS, can rescue primary B lympho-
cytes from in vitro spontaneous apoptosis and, like LPS, can also
induce B cell proliferation and Ig isotype switching. In addition,
CD40 has its unique functions in B cell activation such as
homotypic aggregation and germinal center formation, which
are not shared by either LPS or BAFF. To understand the
contribution of both type 1 and type 2 NF-B pathways in
CD40-mediated common (shared by BAFF and LPS) and
unique events in B cell activation, we first compared the capacity
of CD40, BAFF receptor (BAFF-R), and Toll-like receptor
(TLR) 4 (receptor for LPS) to induce these two pathways in the
context of primary murine splenic B cells.
First, B cells harvested from WT mice were cultured for 24 h
in medium alone or in the presence of 15 gml of an agonistic
anti-CD40 mAb, 100 ngml hBAFF, or 5 gml LPS (these
concentrations were used for all subsequent stimulations unless
otherwise stated). Whole-cell lysate was collected, and the
processing of p100 to p52 was assessed by Western blot analysis
as an indication of the activation of the type 2 pathway. Anti-
CD40 and hBAFF treatment, but not LPS treatment, of B cells
resulted in the processing of p100 to p52 (Fig. 1A). To better
understand the kinetics of type 1 and type 2 NF-B activation by
these stimuli, WT B cells were cultured in the presence of
anti-CD40 mAb, hBAFF, or LPS for 4, 12, and 24 h. Nuclei were
harvested and lysed for detection of p65 (a type 1 indicator) and
p52 (from type 2 activation) nuclear translocation by Western
blot. Results showed that only CD40 ligation led to sustained
nuclear translocation of both p65 and p52, providing a possible
explanation for the unique set of biological activities associated
with CD40 in comparison with BAFF-R and TLR4 (Fig. 1B).
CD40-Stimulated B Cells Retain Significant Survival After Either Single
or Compound Loss of Rel Family Members. B cells from WT, p50/,
c-Rel/, and p52/ mice were stimulated in medium alone or
with anti-CD40 mAb, hBAFF, or LPS for 48 h. Ligand-induced
survival is reported as the percentage of specific viability (see
Fig. 2) to adjust for differences across the various genotypes for
unstimulated cells to remain viable. Whereas CD40-ligated B
cells showed a minor reduction in cell survival in each Rel
knockout background, hBAFF- and LPS-treated B cells dis-
played significant reduction in viability in this context. Specifi-
cally, the loss of p50 or c-Rel, but not p52, greatly reduced
LPS-mediated survival, whereas the loss of p50 or p52, but not
c-Rel, greatly reduced the rescue signal provided by hBAFF (Fig.
2A Upper). Previous work has shown that compound Rel defi-
ciency, specifically dual loss of p50 and c-Rel, completely
abrogates LPS-mediated survival of primary B cells (21). To
examine whether the same were true for CD40- and hBAFF-
mediated survival, WT, p50/c-Rel/, and p50/c-Rel/
p65/ B cells were stimulated as above. As expected, LPS was
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incapable of providing a rescue signal in the compound Rel-
deficient backgrounds. CD40 and BAFF-R ligation, on the other
hand, retained approximately half of their WT survival signal in
these same backgrounds (Fig. 2 A Lower).
To better understand the capacity of CD40 ligation to elicit
significant survival in a compound Rel-deficient background,
we compared the ability of anti-CD40 mAb, hBAFF, and LPS
treatment to regulate the induction of Bcl-xL in WT and
p50/c-Rel/p65/ B cells. First, RNA and whole-cell lysate
isolated from WT B cells stimulated with anti-CD40 mAb,
hBAFF, or LPS was used to analyze Bcl-xL mRNA and protein
by Northern and Western blot, respectively. As shown in Fig. 2B
Left, anti-CD40 and LPS treatment, but not hBAFF treatment,
of B cells led to significant induction of Bcl-xL mRNA. Inter-
estingly, anti-CD40 treatment was able to maintain Bcl-xL in-
duction much longer than LPS. In accordance with the Northern
blot result, Western blot analysis demonstrated the ability of
anti-CD40 and LPS treatment, but not hBAFF treatment, of B
cells to induce significant Bcl-xL protein (Fig. 2B Right). In
addition, CD40 ligation led to higher levels of Bcl-xL protein than
did LPS treatment, likely because of sustained Bcl-xL mRNA
levels mediated by CD40. Next, WT and p50/c-Rel/p65/
B cells were stimulated with anti-CD40 mAb or LPS for 24 h.
Intracellular staining of Bcl-xL protein showed that anti-CD40
and LPS treatment of WT B cells led to a significant increase in
Bcl-xL protein in agreement with Western blot results (Fig. 2C
Left). Simultaneous loss of p50, c-Rel, and one allele of p65,
however, completely blocked LPS induction of Bcl-xL protein
whereas CD40-mediated induction, although significantly dimin-
ished, was clearly measurable, thus providing some explanation
for the capacity of CD40 to elicit significant rescue from
apoptosis in the context of compound Rel deficiency.
Type 1 NF-B Activity Mediated CD40-Induced Proliferation of Primary
B Cells. Previous studies have shown type 1 NF-B activity to be
crucial for LPS- and anti-IgM-induced cell cycle entry of primary
murine B cells (14, 22). However, the ability of CD40 to activate
both type 1 and type 2 NF-B activity, unlike LPS or anti-IgM,
may render CD40-mediated cell cycle entry less sensitive (as
seen in CD40-mediated survival) to deficiency in type 1 Rel
family members. To examine this possibility, RNA from WT B
cells cultured in the presence of anti-CD40 mAb, hBAFF, or LPS
was isolated for Northern blot analysis of the G1–S transition
genes c-Myc, CDK4, and cyclin D2. As expected, anti-CD40 and
LPS treatment, but not hBAFF treatment, led to marked induc-
Fig. 1. CD40 ligation, but not hBAFF or LPS treatment, of primary B cells
activates both type 1 and type 2 NF-B activity. (A) p100 processing to p52. WT
B cells were cultured in medium alone (MC) or in the presence of hBAFF,
anti-CD40 mAb, or LPS for 24 h. Whole-cell lysates were Western-blotted for
p52 and actin (loading control). (B) p65 and p52 nuclear translocation. WT B
cells were cultured with hBAFF, anti-CD40 mAb, or LPS for the indicated times.
Nuclear extracts were Western-blotted for p65, p52, and upstream stimulatory
factor 2 (USF2; loading control). Data are representative of three experiments.
Fig. 2. CD40 ligation, but not hBAFF or LPS treatment, of primary B cells maintains significant signal-induced survival in the context of both single and compound
Rel family member deficiency. (A) Cell survival. B cells from WT, p50/, c-Rel/, p52/, p50/c-Rel/, and p50/c-Rel/p65/mice were cultured in triplicate
for 48 h with anti-CD40 mAb, hBAFF, or LPS. Propidium iodide-annexin double-negative cells were used to determine the percentage of specific viability
[(ligand-mediated viabilitymedium-mediated)(100medium-mediated)]. Data represent the mean SD of three experiments. (B) Bcl-xL induction. RNA and
whole-cell extract was prepared from WT B cells cultured with anti-CD40 mAb, hBAFF, or LPS for the indicated times. Bcl-xL mRNA and protein levels were
analyzed by Northern and Western blot, respectively. Actin and 28s RNA levels served as loading controls. (C) WT and p50/c-Rel/p65/ B cells were cultured
with medium alone (4 h) and anti-CD40 mAb or LPS (24 h). Cells were permeabilized and stained with anti-Bcl-xL and rabbit IgG as a control. Intracellular staining
was executed twice with similar results.
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tion of these genes (Fig. 3A). Next, RNA from WT, p50/,
c-Rel/, and p50/c-Rel/ B cells cultured with anti-CD40
mAb or LPS was isolated for cDNA synthesis, and Q-PCR was
used for detection of c-Myc and cyclin D2 levels. As shown in Fig.
3B, loss of c-Rel was sufficient to block CD40-mediated induc-
tion of both c-Myc and cyclin D2. To further verify that type 1
NF-B activity controls CD40-mediated cell cycle entry of
primary B cells, WT, p52/, and p50/c-Rel/ B cells were
stimulated for 48 h with titrations of anti-CD40 mAb or LPS. Cell
cycle entry was measured by means of addition of [3H]thymidine
20 h poststimulation. Although loss of p52 did not affect either
CD40- or LPS-mediated DNA synthesis (Fig. 3C Upper), CD40-
mediated cell cycle entry was blocked in the context of com-
pound type 1 Rel deficiency, as published for LPS and anti-IgM
(Fig. 3C Lower).
CD40-Mediated Homotypic Aggregation of B Cells Requires Type 1 and
Type 2 NF-B Pathways. CD40 ligation on primary B cells is known
to induce striking and highly stable homotypic aggregates by 24 h
of culture (23, 24). To examine the contribution of both type 1
and type 2 NF-B pathways in CD40-mediated homotypic
aggregation, WT, p50/, c-Rel/, and p52/ B cells were
stimulated with anti-CD40 mAb, hBAFF, or LPS for 24 h. As
shown in Fig. 4, anti-CD40 treatment, but not hBAFF or LPS
treatment, of WT cells induced B cell aggregation. In addition,
CD40-mediated homotypic aggregation was found to require the
presence of both c-Rel and p52. Some have speculated that an
unidentified B cell chemokine may also be involved in CD40-
mediated B cell homotypic aggregation. To explore this possi-
bility, conditioned medium from WT B cells stimulated with
anti-CD40 mAb for 24 h was supplied with fresh Ab and used to
stimulate c-Rel/ and p52/ B cells. No rescue of homotypic
aggregation was observed (data not shown).
Complete CD40-Mediated Gene Program Requires Activation of Type
1 and Type 2 NF-B Pathways. To further address the significance
of CD40-mediated activation of both type 1 and type 2 NF-B
pathways in primary B cells, we sought to compare CD40-
mediated gene activation with that elicited by LPS or hBAFF.
Through analysis of a gene panel including targets induced by
both anti-CD40 and LPS treatment (but not hBAFF treatment)
of B cells and genes common to anti-CD40 and hBAFF treat-
ment (but not LPS treatment) of B cells, we could test the
prediction that the former category would be sensitive to the loss
of type 1 NF-B activity and that the latter would be sensitive to
the loss of type 2 NF-B activity. First, Northern blot analyses
of RNA purified from WT B cells cultured with anti-CD40 mAb,
hBAFF, or LPS revealed gene(s) whose activation was common
to CD40 and TLR4 ligation [AID and UNG, both crucial to Ig
isotype switching and affinity maturation (25–28)], specific to
CD40 ligation [Entactin, important in lymphocyte adhesion
migration (29, 30)], and common to CD40 and BAFF-R ligation
[LEF-1, involved in propre-B cell development and prolifera-
tion (31)] (Fig. 5A). To determine the contribution of type 1 and
type 2 NF-B pathway activation to induction of these genes,
RNA was isolated from WT, p50/, c-Rel/, and p52/ B
cells stimulated with anti-CD40 mAb and analyzed by Northern
blot (Fig. 5B). As predicted, genes activated by CD40 and TLR4
ligation and not BAFF-R, namely AID and UNG, required type
1 and not type 2 NF-B activity. Specifically, loss of p50 or c-Rel
prevented CD40-mediated induction of AID, whereas loss of
Fig. 3. Loss of type 1, but not type 2, NF-B activity blocks CD40-mediated proliferation of primary B cells. (A) Induction of G1–S cell cycle transition genes. B
cells from WT mice were stimulated with anti-CD40 mAb, hBAFF, or LPS. RNA was collected for analysis of c-Myc, CDK4, and cyclin D2 by Northern blot. (B)
Contribution of type 1 NF-B to c-Myc and cyclin D2 induction. WT (lane 1), p50/ (lane 2), c-Rel/ (lane 3), and p50/c-Rel/ (lane 4) B cells were stimulated
with medium (open bars), anti-CD40 (filled bars), and LPS (hatched bars) for 12 h. RNA was isolated for Q-PCR analysis of the indicated genes. (C) DNA synthesis.
WT (solid lines in Upper and Lower), p52/ (broken lines in Upper), and p50/c-Rel/ (broken lines in Lower) B cells were stimulated in triplicate with a 3-fold
dilution series of anti-CD40 mAb (squares), hBAFF (circles), or LPS (triangles) for 48 h. The high dose of each ligand, labeled 6, was 45, 0.9, and 30 gml for
anti-CD40 mAb, hBAFF, and LPS, respectively. DNA synthesis was measured by addition of [3H]thymidine at 20 h poststimulation. Data represent the mean SD
of two experiments.
Fig. 4. CD40-mediated homotypic aggregation of primary B cells requires
both type 1 and type 2 NF-B activity. Homotypic aggregation is shown. 5E6
B cells from WT, p50/, c-Rel/, and p52/mice were stimulated in a 24-well
format for 24 h with anti-CD40 mAb, hBAFF, or LPS. Pictures are of represen-
tative fields at 4 magnification.
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c-Rel, but not p50 or p52, delayed and reduced CD40-mediated
induction of UNG. Furthermore, CD40-mediated induction of
LEF-1 required p52, whereas loss of p50 actually enhanced
induced mRNA levels. Interestingly, the CD40-specific target,
Entactin, was found to require both type 1 and type 2 NF-B
pathways because loss of p50, c-Rel, or p52 markedly reduced
induced message levels.
Discussion
Primary B cells can be activated by means of a diverse set of
surface receptors, including mediators of both innate and adap-
tive immunity. Upon ligation, such receptors, including CD40,
BCR, TLR4, and TLR9, activate similar biochemical pathways,
making it difficult to explain the mechanism of divergence in
their respective gene expression profiles and induced cellular
responses. However, studies on the mechanism of combinatorial
control of gene regulation have revealed that variation in
biochemical pathway activation results in marked differences in
gene activation potential.
Previous work in our laboratory used high-density oligonu-
cleotide arrays to compare the gene expression profiles of
CD40L and LPS treatment of primary murine B cells (17).
Although these stimuli share the ability to activate the c-Jun
N-terminal kinasestress-activated protein kinase, p38, phos-
phatidylinositol 3-kinase, and extracellular signal-regulated
kinasemitogen-activated protein kinase pathways, in addition
to type 1 NF-B activity, we identified gene activation unique to
each ligand. Subsequent work revealed the capacity of LPS to
specifically activate the transcription factor IFN regulatory
factor 3 (32), which, together with NF-B, mediated the induc-
tion of a large set of the LPS-specific genes identified in our
previous microarray study (20). In this work, we explored the
contribution of type 1 and type 2 NF-B pathways to B cell
activation, and we provide evidence of type 2 NF-B activity as
a possible explanation for unique CD40-mediated gene activa-
tion and cellular responses.
Primary B cells rapidly undergo spontaneous apoptosis in
culture even in the presence of serum. Although treatment with
CD40L, BAFF, and LPS can all rescue B cells from apoptosis,
we found that they had differential requirements for individual
NF-B subunits (see Fig. 2 A Upper). In addition, whereas
compound deficiency in type 1 Rel members completely blocked
LPS-mediated survival, CD40 ligation retained a significant
survival signal in this context (see Fig. 2 A Lower). Intracellular
staining of Bcl-xL verified the capacity of CD40 ligation to induce
a survival factor in p50/c-Rel/p65/ B cells (see Fig. 2C).
Although we cannot exclude the contribution of other survival
pathways, the remaining NF-B activity, especially the ability of
CD40 ligation to activate both type 1 and type 2 NF-B
pathways, is most likely involved in CD40-mediated survival of
these cells, because the total NF-B inhibitors, Gliotoxin (20S
and 26S proteasome inhibitor) and SN50 (a cell-permeable
peptide that binds the Rel nuclear localization sequence), com-
pletely blocked CD40-mediated survival (data not shown). In
support of this, we found that loss of p52 had an even greater
affect than loss of p50 (33) on the ability of hBAFF to provide
a rescue signal to B cells, implying that p52 can replace a
significant portion of CD40-mediated survival lost in the absence
of multiple type 1 Rel family members.
In contrast to cell survival, CD40-mediated induction of genes
involved in cell proliferation (c-Myc, CDK4, or cyclin D2) and Ig
isotype switching (AID and UNG) seems to depend mostly on
type 1 but not type 2 NF-B activity. This is consistent with the
observation that CD40L and LPS but not BAFF can strongly
promote resting B lymphocytes for cell cycle entry and prolif-
eration. Our gene expression studies are also consistent with
previous functional studies indicating that deficiency in either
p50 or c-Rel prevents Ig isotype switching elicited by multiple
stimuli (13, 34).
In addition to common functions such as proliferation and
survival, CD40 ligation of primary B cells induces cellular
responses not shared by either LPS or hBAFF. Our analysis of
type 1 and type 2 NF-B contribution supports a model by which
CD40L, LPS, and hBAFF common outcomes result from the
shared capacity to activate either type 1 or type 2 NF-B,
whereas the unique functions of CD40 result from the capacity
to activate both pathways (Fig. 6). Indeed, examination of
CD40-mediated homotypic aggregation revealed that both path-
ways are required, because loss of c-Rel or p52 greatly reduced
the formation of stable aggregates (see Fig. 4). In addition,
Northern blot analysis of type 1 and type 2 NF-B contribution
to CD40-mediated induction of Entactin and LEF-1 (two genes
induced by CD40L but not LPS by microarray analysis) revealed
that LEF-1 required the presence of p52 whereas Entactin
required both type 1 and type 2 NF-B activity. Further studies
are required to examine the mechanism of cooperative type 1
Fig. 5. Type 1 and type 2 NF-B pathways mediate the CD40-induced gene program in primary B cells. (A) Gene induction program. WT B cells were cultured
in medium alone (4 h) and in the presence of anti-CD40 mAb, hBAFF, or LPS over an extended time course. RNA was purified, and the indicated genes were
analyzed by Northern blot. (B) Type 1 and type 2 NF-B contribution to CD40-induced genes. WT, p50/, c-Rel/, and p52/ B cells were cultured in medium
alone (4 h) and in the presence of anti-CD40 mAb over an extended time course. Purified RNA was isolated, and the indicated genes were analyzed by Northern
blot. Representative gene induction profiles are shown.
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and type 2 NF-B activity to unique CD40-mediated B cell
responses. Although CD40 ligation of B cells leads to the
immediate and sustained activation of the type 1 pathway, strong
activation of the type 2 pathway, for poorly understood reasons,
requires substantial time. It is still not clear whether unique
CD40-mediated B cell responses require specific periods of type
1 and type 2 NF-B synergy. To this point, it is worth noting that
combinatorial treatment of WT B cells with LPS and hBAFF,
which results in the activation of both type 1 and type 2 NF-B
(data not shown), did not induce homotypic aggregates after 24 h
of stimulation (data not shown). Interestingly, this combinatorial
treatment did result in the formation of spherical clusters after
72 h of stimulation, although not to the extent of CD40 ligation
(B.Z. and G.C., unpublished observations).
Thus, our studies reveal that the CD40-mediated gene expres-
sion and biological program require dual activation of the type
1 and type 2 NF-B pathways. Of course, CD40-mediated
responses in B cells require the activation of additional biochem-
ical pathways [e.g., p38 and extracellular signal-regulated kinase
kinase pathways (17)]. Continued investigation is required to
understand how these signaling circuits cooperate in CD40 signal
transduction and cellular responses. Our results are a reminder
that the mechanisms by which cells execute diverse functions rely
on the ability of different combinations of distinct but mostly
shared stimuli to elicit divergent cellular responses. This phe-
nomenon is no better exemplified than in CD40-mediated, T
cell-dependent immune responses in which activated B cells,
over many days, must integrate dozens of changing signals to
achieve complex ends, including memory and plasma B cell
differentiation.
We thank Dr. Rolf-Peter Ryseck (Bristol-Myers Squibb, Princeton) and
Amgen (Thousand Oaks, CA) for providing p52 knockout mice and
hBAFF. We thank Drs. Hajir Dadgostar (University of California, Los
Angeles) and Xiao-Feng Qin (M. D. Anderson Cancer Center, Houston)
for helpful discussion. J.Q.H. is supported by National Science Foun-
dation GK12 Mathematics and Science Inquiry in Los Angeles Urban
Schools Grant DGE-0231998. G.O. is supported by University of Cali-
fornia at Los Angeles Medical Scientist Training Program Training
Grant GM08042. G.C. is a Research Scholar supported by the Leukemia
and Lymphoma Society of America. Part of this work was supported by
National Institutes of Health Grants R01 GM57559 and R01 CA87924.
1. Calderhead, D., Kosaka, Y., Manning, E. & Noelle, R. (2002) Curr. Top.
Microbiol. Immunol. 245, 73–99.
2. Foy, T., Laman, J., Ledbetter, J., Aruffo, A., Claassen, E. & Noelle, R. (1994)
J. Exp. Med. 180, 157–163.
3. Kopp, E. B. & Ghosh, S. (1995) Adv. Immunol. 58, 1–27.
4. Baeuerle, P. A. & Baltimore, D. (1996) Cell 87, 13–20.
5. Karin, M. & Ben-Neriah, Y. (2000) Annu. Rev. Immunol. 18, 621–663.
6. Zandi, E. & Karin, M. (1999) Mol. Cell. Biol. 19, 4547–4551.
7. Woronicz, J. D., Gao, X., Cao, Z., Rothe, M. & Goeddel, D. V. (1997) Science
278, 866–869.
8. Sizemore, N., Lerner, N., Dombrowski, N., Sakurai, H. & Stark, G. R. (2002)
J. Biol. Chem. 277, 3863–3869.
9. Yamaoka, S., Courtois, G., Bessia, C., Whiteside, S. T., Weil, R., Agou, F., Kirk,
H. E., Kay, R. J. & Israel, A. (1998) Cell 93, 1231–1240.
10. Matsushima, A., Kaisho, T., Rennert, P. D., Nakano, H., Kurosawa, K., Uchida,
D., Takeda, K., Akira, S. & Matsumoto, M. (2001) J. Exp. Med. 193, 631–636.
11. Dejardin, E., Droin, N. M., Delhase, M., Haas, E., Cao, Y., Makris, C., Li,
Z. W., Karin, M., Ware, C. F. & Green, D. R. (2002) Immunity 17, 525–535.
12. Sha, W. C., Liou, H. C., Tuomanen, E. I. & Baltimore, D. (1995) Cell 80,
321–330.
13. Snapper, C. M., Rosas, F. R., Zelazowski, P., Moorman, M. A., Kehry, M. R.,
Bravo, R. & Weih, F. (1996) J. Exp. Med. 184, 1537–1541.
14. Grumont, R. J., Rourke, I. J., O’Reilly, L. A., Strasser, A., Miyake, K., Sha, W.
& Gerondakis, S. (1998) J. Exp. Med. 187, 663–674.
15. Caamano, J. H., Rizzo, C. A., Durham, S. K., Barton, D. S., Raventos-Suarez,
C., Snapper, C. M. & Bravo, R. (1998) J. Exp. Med. 187, 185–196.
16. Yilmaz, Z. B., Weih, D. S., Sivakumar, V. & Weih, F. (2003) EMBO J. 22,
121–130.
17. Dadgostar, H., Zarnegar, B., Hoffmann, A., Qin, X. F., Truong, U., Rao, G.,
Baltimore, D. & Cheng, G. (2002) Proc. Natl. Acad. Sci. USA 99, 1497–1502.
18. Tumanov, A., Kuprash, D., Lagarkova, M., Grivennikov, S., Abe, K., Shakhov,
A., Drutskaya, L., Stewart, C., Chervonsky, A. & Nedospasov, S. (2002)
Immunity 17, 239–250.
19. Lee, H. H., Dadgostar, H., Cheng, Q., Shu, J. & Cheng, G. (1999) Proc. Natl.
Acad. Sci. USA 96, 9136–9141.
20. Doyle, S., Vaidya, S., O’Connell, R., Dadgostar, H., Dempsey, P., Wu, T., Rao,
G., Sun, R., Haberland, M., Modlin, R. & Cheng, G. (2002) Immunity 17,
251–263.
21. Pohl, T., Gugasyan, R., Grumont, R. J., Strasser, A., Metcalf, D., Tarlinton, D.,
Sha, W., Baltimore, D. & Gerondakis, S. (2002) Proc. Natl. Acad. Sci. USA 99,
4514–4519.
22. Tumang, J. R., Owyang, A., Andjelic, S., Jin, Z., Hardy, R. R., Liou, M. L. &
Liou, H. C. (1998) Eur. J. Immunol. 28, 4299–4312.
23. Barrett, T. B., Shu, G. & Clark, E. A. (1991) J. Immunol. 146, 1722–1729.
24. Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y. & Honjo,
T. (2000) Cell 102, 553–663.
25. Arakawa, H., Hauschild, J. & Buerstedde, J. M. (2002) Science 295, 1301–1306.
26. Imai, K., Slupphaug, G., Lee, W. I., Revy, P., Nonoyama, S., Catalan, N., Yel,
L., Forveille, M., Kavli, B., Krokan, H. E., et al. (2003) Nat. Immunol. 4,
1023–1028.
27. Rada, C., Williams, G. T., Nilsen, H., Barnes, D. E., Lindahl, T. & Neuberger,
M. S. (2002) Curr. Biol. 12, 1748–1755.
28. Li, Y. & Cheung, H. (1992) J. Immunol. 149, 3174–3181.
29. Savin, W., Dalmau, S. R. & Dealmeida, V. C. (2000) Dev. Immunol. 7, 279–291.
30. Reya, T., O’Riordan, M., Okamura, R., Devaney, E., Willert, K., Nusse, R. &
Grosschedl, R. (2000) Immunity 13, 15–24.
31. Jin, Z. X., Kishi, H., Wei, X. C., Matsuda, T., Saito, S. & Muraguchi, A. (2002)
J. Immunol. 169, 3783–3792.
32. Kawai, T., Takeuchi, O., Fujita, T., Inoue, J., Muhlradt, P. F., Sato, S., Hoshino,
K. & Akira, S. (2001) J. Immunol. 167, 5887–5894.
33. Hatada, E. N., Do, R. K., Orlofsky, A., Liou, H. C., Prystowsky, M.,
MacLennan, I. C., Caamano, J. & Chen-Kiang, S. (2003) J. Immunol. 171,
761–768.
34. Kontgen, F., Grumon, R., Strasser, A., Metcalf, D., Li, R., Tarlinton, D. &
Gerondakis, S. (1995) Genes Dev. 9, 1965–1977.
Fig. 6. A model for the contribution of type 1 and type 2 NF-B in LPS-,
CD40L-, and BAFF-induced B cell activation. CD40L activation of primary B cells
shares common cellular outcomes with both LPS- and BAFF-mediated activa-
tion. In each case, these shared functions result from the shared capacity of
these ligands to activate either type 1 or type 2 NF-B activity. In addition,
CD40L’s ability to activate both type 1 and type 2 NF-B activity results in
unique, CD40-specific B cell responses.
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